News | August 13, 2021
Wockhardt to manufacture and supply Sputnik V
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
Income declines marginally
A treatment to prevent extreme symptoms and cut hospitalisation
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Subscribe To Our Newsletter & Stay Updated
